Quarterly Pricing Pulse — Q3 2026

AbbVie filed multiple material events around Botox/Juvéderm and Allē loyalty (June 22, May 12, April 29). The pattern is clear: rebate programs are consolidating around bundled, tiered loyalty rather than per-unit discounts. Practices locked into older, transactional pricing are seeing effective cost-per-unit rise as Allē enrollment becomes a prerequisite for competitive rates. Action: Audit your Allē tier now. If you're not at the highest rebate level, calculate the patient-acquisition cost of enrollment vs. the margin you're leaving on the table. Many practices find that aggressive Allē sign-up campaigns (email, SMS, in-office signage) recoup 2–4% margin within 90 days. Don't assume your current tier is optimal—AbbVie's Q3 moves suggest tier thresholds shifted.

Evolus filed four material events this quarter (June 12, May 4, March 13, and earlier) announcing Jeuveau and Evolus Rewards aggressive medspa targeting. Jeuveau pricing is now the market floor for botulinum toxin. Evolus is bundling rebates with loyalty to undercut AbbVie and Merz on per-unit cost. Action: If you haven't benchmarked Jeuveau pricing vs. your current Botox/Xeomin contract, do it now. Many practices find Jeuveau's rebate structure 8–12% cheaper per unit, but only if you commit to volume thresholds. The trade-off: Jeuveau has smaller market share and lower patient brand recognition. Consider a dual-source strategy: stock Jeuveau for price-sensitive or new patients, reserve premium brands for established clients. This protects margin while capturing price-conscious volume.

Q3 saw multiple filler trial completions (HArmonyCa, Restylane Lyft chin, Ultracol, Algeness, LMW-CL-HA-FACE/BODY) and new recruiting studies (Cellbooster Shape, Dr Korman HA filler). The filler category is maturing—more products, more competition, less pricing differentiation. Galderma's Restylane Lyft chin trial completion signals imminent label expansion and likely generic/biosimilar pressure. Action: Filler pricing is inelastic downward; instead, bundle fillers with complementary services (HydraFacial, skin-tightening, toxin) to preserve blended margins. Practices reporting stable filler revenue are those selling integrated packages, not à la carte syringes. Review your filler mix: are you still stocking premium brands at premium prices, or have you shifted to mid-tier fillers with better rebates?

Hims & Hers filed three material events (June 15, June 2, May 21) on telehealth GLP-1 compounding; Eli Lilly filed four (May 20, May 7, April 30) on Zepbound/Mounjaro supply and compounding rules; Viking Therapeutics filed three (May 26, April 29, Feb 11) on next-gen VK2735 dual-agonist pipeline. GLP-1 supply is normalizing, pricing is falling, and telehealth competition is intensifying. Practices that built GLP-1 as a high-margin cash-pay service are now competing with $99–$199/month telehealth options. Action: If you offer GLP-1, shift from margin-per-injection to retention and bundling: tie GLP-1 to aesthetic maintenance (toxin, filler, skin) to increase lifetime value. Alternatively, deprioritize GLP-1 and redirect cash-pay capacity to injectables, skin-tightening, and body contouring—categories where telehealth has no foothold.

The Beauty Health Company (HydraFacial) filed two material events (June 22, June 16, May 12); Apyx Medical (Renuvion) filed three (June 17, May 21, May 14); Bausch Health (Solta) filed three (May 19, April 29, March 2). HydraFacial consumable demand is steady, Renuvion adoption is accelerating, and Solta faces potential M&A/spin-off disruption. If you rely on Solta devices (Thermage, Fraxel, Clear+Brilliant), watch for supply or support changes post-transaction. Action: Audit your device-support contracts now. If you're on Solta, confirm consumable pricing and training continuity. For HydraFacial, consumable costs are stable—use it as a high-frequency, low-margin traffic driver to bundle with injectables. Renuvion is gaining traction; if you don't offer skin-tightening, consider adding it as a non-invasive alternative to surgical body contouring.

An FDA Class II recall hit Payless Compounders for semaglutide-glycine-cyanocobalamin (lack of sterility assurance). Compounded GLP-1 and aesthetic injectables face tightening FDA oversight. If you source compounded products, verify USP <797> compliance and supplier credentials now. Action: Audit your compounding suppliers. If you use compounded botulinum toxin, fillers, or GLP-1, confirm they hold current USP <797> certification and have passed recent FDA inspections. The cost of switching suppliers is lower than the liability of a contamination event. Consider shifting to branded, FDA-approved products where margin allows—the regulatory tail risk is not worth 5–10% savings on compounded alternatives.